 Kazia Therapeutics Ltd ASX:KZA NASDAQ:KZIA FRA:NV9 has secured an increased price target from A2.25 to A2.60 a share by Corporate Connect analyst Marc Sinatra on the back of two recent licensing deals. The company signed an licensing deal with China-based Simcere Pharmaceutical Group Limited HKSE:2906 for paxalisib in Greater China and earlier in March with Oasmia Pharmaceutical AB STO: OASM OTCMKTS:OASMY for worldwide rights to Cantrixil. 